pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS
Genzyme Europe
Apellis Europe B.V.
Genzyme Europe clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
- Founded
- 1981
- Employees
- 273
- Programs
- 20
- Drugs
- 5
- Patents
- 24
Genzyme Europe projects
9 ClinicalTrials.gov programs sponsored by Genzyme Europe.
Genzyme Europe has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
APL-2
Apellis Europe B.V.
IgA Nephropathy
1 trial -
APL-2
Apellis Europe B.V.
Warm Autoimmune Hemolytic Anemia
1 trial -
APL-3007, pegcetacoplan (APL-2)
Apellis Europe B.V.
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 trial -
APL-9
Apellis Europe B.V.
COVID
1 trial -
Pegcetacoplan
Apellis Europe B.V.
Transplant-Associated Thrombotic Microangiopathy
1 trial -
Pegcetacoplan
Apellis Europe B.V.
Geographic Atrophy
1 trial -
Pegcetacoplan
Apellis Europe B.V.
Neovascular Age-related Macular Degeneration
2 trials -
Pegcetacoplan
Apellis Europe B.V.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
2 trials -
Pegcetacoplan (APL-2)
Apellis Europe B.V.
Amyotrophic Lateral Sclerosis
1 trial
Frequently asked questions
How many clinical projects does Genzyme Europe have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.